Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY12378 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Study Information
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY21108 GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer The primary objective is to determine Progression-free Survival (PFS) by RECIST 1.1. To determine Objective Response Rate (ORR) and Duration of Response (DOR) by RECIST 1.1, PFS by RECIST 1.1 (in modified population), PFS by iRECIST, Overall Survival (OS), and safety. Study Information
STUDY21565 A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.) To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s) To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS], and duration of response [DOR]) of E7386 in combination with other anticancer drug(s) (Revised per Amendment 06) Study Information
STUDY23164 3068/217908 A Phase III Randomized Trial of Heated Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer To determine if a single treatment with intraoperative HIPEC with cisplatin at the time of iCRS will result in improved PFS as compared to iCRS alone in patients with stage III or IV EOC who are treated with neoadjuvant IV platinum-based chemotherapy followed by niraparib maintenance. Study Information